This article is more than 5 years old. Information may no longer be current.

VIDEO: New IL-17 receptor antagonist for psoriasis near FDA approval

MIAMI BEACH, Florida — At South Beach Symposium 2017, Leon Kircik, MD, reported on emerging therapies for the treatment of psoriasis, including new biologics and new pathways.

Editor's note: The FDA announced today, Feb. 16, 2017, that it has approved Siliq (brodalumab, Valeant Pharmaceuticals) as treatment for moderate-to-severe plaque psoriasis.